Form 4: Haemonetics EVP, Chief Operating Officer Frank Chan Reports Acquisition of Restricted Stock Units and Stock Options

Frank Chan, EVP and COO of Haemonetics, reports the acquisition of 5,689 restricted stock units and 12,317 stock options.

Summary

• Frank Chan, the EVP and Chief Operating Officer of Haemonetics Corporation, filed a Form 4 on May 20, 2025.
• The report details the acquisition of 5,689 restricted stock units (RSUs) and 12,317 non-qualified stock options on May 16, 2025.
• The RSUs vest in three equal annual installments starting on the first anniversary of the grant date.
• Each RSU represents a contingent right to receive one share of Haemonetics common stock when vested.
• The stock options have an exercise price of $70.31 and vest in annual increments of 25% beginning on the first anniversary of the grant date, expiring on 05/16/2032.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, and the sentiment is neutral. It simply reports transactions by an executive.

Positives

• The acquisition of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules for both RSUs and stock options encourage long-term commitment from the executive.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of RSUs and stock options aligns the executive's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term performance.

Key Dates

Keywords

Form 4, Haemonetics, Frank Chan, Restricted Stock Units, Stock Options, Beneficial Ownership, EVP, COO